Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
This study has been completed.
Study NCT01339091 Information provided by Durata Therapeutics, Inc.
First Received on April 18, 2011. Last Updated on October 22, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Surgical Site Infection
More general conditions related to this trial
Connective Tissue Diseases
Skin Diseases, Infectious
Wounds and Injuries
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Protein Synthesis Inhibitors
Sponsors listed in this trial
Durata Therapeutics, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers